Skip to content
OpenCapital
Get started

NewAmsterdam Pharma Company NAMS Current ratio

Current ratio at other companies

Merck & Co. logo
Merck & Co.MRK
1.3×-0.1×
Amgen logo
AmgenAMGN
1.3×+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
Eli Lilly logo
Eli LillyLLY
1.5×+0.1×
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
9.3×-0.3×

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp

Where this comes from

Calculated from NewAmsterdam Pharma Company’s reported figures.

total current assets/total current liabilities=9.8×

Based on the most recent quarter.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's current ratio?
NewAmsterdam Pharma Company (NAMS) reported current ratio of 9.8× in Q1 2026.
How has NewAmsterdam Pharma Company's current ratio changed year-over-year?
NewAmsterdam Pharma Company's current ratio decreased by 51.1% year-over-year, from 20× to 9.8×.
What is the long-term trend for NewAmsterdam Pharma Company's current ratio?
Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's current ratio has grown at a -15.9% compound annual growth rate (CAGR), from 13.3× to 7.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.